SuperGen, Inc. (NASDAQ:SUPG), a pharmaceutical company dedicated
to the discovery and development of novel cancer therapies,
announced that its chairman, president and chief executive officer,
James S.J. Manuso, Ph.D., has been elected to the Full Board of
Directors of the Biotechnology Industry Organization (BIO) at its
2011 International Convention.
“I am honored to serve on the BIO Board of Directors,” said Dr.
Manuso. “Collaborating with such an esteemed group of international
life sciences leaders on health policy affecting oncology patients
and those with other serious illnesses will hopefully enhance the
effectiveness with which medical therapies are discovered,
approved, and delivered.”
BIO’s Board of Directors is composed of members of the Governing
Boards for each of BIO’s four sections: Health, Emerging
Companies, Industrial & Environmental and Food &
Agriculture. Dr. Manuso will serve on BIO’s Health Section
Governing Board.
“I want to welcome Dr. Manuso to the Board, we are proud that he
will be serving on BIO’s Full Board of Directors and on the Health
Section Governing Board,” said Jim Greenwood, President and CEO of
BIO. “His expertise and experience will be highly valuable to BIO’s
critical policy development and advocacy activities.”
In addition, Dr. Manuso will serve on the BIO Board Standing
Committee on International Affairs.
SuperGen has been a member of BIO since 2003. In addition to Dr.
Manuso’s appointment to the Board, Nancy Worrell, SuperGen
executive director, human resources, is the Co-Chair of the BIO
Human Resources Conference 2011. The BIO Human Resources Conference
2011 has integrated events and offerings from the BIO International
Convention.
About James S.J. Manuso, Ph.D.
Dr. Manuso has served as SuperGen chairman, president and chief
executive officer since January 1, 2004, as chief executive
officer-elect from September 2003 to December 2003 and as a
director since February 2001. He is co-founder and immediate past
president and chief executive officer of Galenica Pharmaceuticals,
Inc.
Dr. Manuso co-founded and was general partner of PrimeTech
Partners, a biotechnology venture management partnership, from 1998
to 2002, and co-founder and managing general partner of The Channel
Group LLC, an international life sciences corporate advisory firm.
He was also president of Manuso, Alexander & Associates, Inc.,
management consultants and financial advisors to pharmaceutical and
biotechnology companies.
Dr. Manuso was a vice president and director of Health Care
Planning and Development for The Equitable Companies (now Group
Axa), where he also served as an acting medical director. He
currently serves on the boards of Novelos Therapeutics, Inc.
(NVLT:OB) and privately-held KineMed, Inc. Previously, he served on
the boards of Merrion Pharmaceuticals Ltd. (MERR:IEX; Dublin,
Ireland), Inflazyme Pharmaceuticals, Inc., Symbiontics, Inc.
(subsequently sold to BioMarin as ZyStor Therapeutics, Inc.), Quark
Pharmaceuticals, Inc., Galenica Pharmaceuticals, Inc., and Supratek
Pharma, Inc.
Dr. Manuso earned a B.A. with Honors in Economics and Chemistry
from New York University, a Ph.D. in Experimental Psychophysiology
from the Graduate Faculty of The New School University, a
Certificate in Health Systems Management from Harvard Business
School, and an Executive M.B.A. from Columbia Business School.
Dr. Manuso is the author of over 30 chapters, articles and books
on topics including health care cost containment and biotechnology
company management. He has taught and lectured at Columbia, New
York University, Georgetown, Polytechnic University, and Waseda
University (Japan). He has delivered invited addresses at meetings
of the American Management Association, the American Medical
Association, the Securities Industry Association, the Biotechnology
Industry Organization, and many other professional associations.
Dr. Manuso previously served as vice president and a member of the
Board of Trustees of the Greater San Francisco Bay Area Leukemia
& Lymphoma Society.
About SuperGen
SuperGen is a pharmaceutical company dedicated to the discovery
and development of novel cancer therapeutics in epigenetic and cell
signaling modulation. The Company develops products through
biochemical and clinical proof of concept to partner for further
development and commercialization. SuperGen developed Dacogen® and
receives significant royalties on global sales.
On April 6, 2011, SuperGen entered into a definitive merger
agreement to acquire Astex Therapeutics Limited, a UK based
biotechnology company. The transaction was approved by SuperGen
stockholders on June 16, 2011 and by Astex Therapeutics
shareholders on June 13, 2011. The transaction is subject to
customary regulatory and legal approvals and is targeted to close
in July 2011.
Further information about this transaction is available at
http://www.astex-supergen.com. For more information about SuperGen,
please visit http://www.supergen.com.
About BIO
The Biotechnology Industry Organization (BIO) represents more
than 1,100 biotechnology companies, academic institutions, state
biotechnology centers and related organizations across the United
States and in more than 30 other nations. BIO members are involved
in the research and development of innovative healthcare,
agricultural, industrial and environmental biotechnology products.
BIO also produces the BIO International Convention, the world’s
largest gathering of the biotechnology industry, along with
industry-leading investor and partnering meetings held around the
world.
Supergen, Inc. (MM) (NASDAQ:SUPG)
Gráfica de Acción Histórica
De May 2024 a Jun 2024
Supergen, Inc. (MM) (NASDAQ:SUPG)
Gráfica de Acción Histórica
De Jun 2023 a Jun 2024
